CN110882282A - Probiotic preparation for conditioning intestinal dysbacteriosis of tumor patients after radiotherapy and chemotherapy and application thereof - Google Patents
Probiotic preparation for conditioning intestinal dysbacteriosis of tumor patients after radiotherapy and chemotherapy and application thereof Download PDFInfo
- Publication number
- CN110882282A CN110882282A CN201911283572.4A CN201911283572A CN110882282A CN 110882282 A CN110882282 A CN 110882282A CN 201911283572 A CN201911283572 A CN 201911283572A CN 110882282 A CN110882282 A CN 110882282A
- Authority
- CN
- China
- Prior art keywords
- parts
- following components
- mass
- lactobacillus
- probiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 62
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 62
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 18
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 17
- 238000002512 chemotherapy Methods 0.000 title claims abstract description 16
- 238000001959 radiotherapy Methods 0.000 title claims abstract description 16
- 230000003750 conditioning effect Effects 0.000 title claims abstract description 13
- 208000036649 Dysbacteriosis Diseases 0.000 title claims abstract description 12
- 208000027244 Dysbiosis Diseases 0.000 title claims abstract description 12
- 230000007140 dysbiosis Effects 0.000 title claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 16
- 235000018102 proteins Nutrition 0.000 claims abstract description 13
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 13
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 13
- 239000011573 trace mineral Substances 0.000 claims abstract description 13
- 239000011782 vitamin Substances 0.000 claims abstract description 13
- 229940088594 vitamin Drugs 0.000 claims abstract description 13
- 229930003231 vitamin Natural products 0.000 claims abstract description 13
- 235000013343 vitamin Nutrition 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 11
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims abstract description 6
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 6
- 241000186012 Bifidobacterium breve Species 0.000 claims abstract description 6
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 6
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 6
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 6
- 241000186840 Lactobacillus fermentum Species 0.000 claims abstract description 6
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 6
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 6
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 6
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 6
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract description 6
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 6
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 6
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 6
- 229940012969 lactobacillus fermentum Drugs 0.000 claims abstract description 6
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- 239000004475 Arginine Substances 0.000 claims description 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 5
- 241000222336 Ganoderma Species 0.000 claims description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 5
- 229930182816 L-glutamine Natural products 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 5
- 108010046377 Whey Proteins Proteins 0.000 claims description 5
- 102000007544 Whey Proteins Human genes 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 235000019206 astragalus extract Nutrition 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 5
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 5
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 5
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 5
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 5
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 5
- 235000021119 whey protein Nutrition 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 230000000694 effects Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
Abstract
The invention discloses a probiotic preparation for conditioning intestinal dysbacteriosis of tumor patients after radiotherapy and chemotherapy and application thereof, and relates to the technical field of probiotic preparations, wherein the probiotic preparation comprises probiotics, vitamins, trace elements, proteins, traditional Chinese medicine extracts, sugar and auxiliary components; the probiotics comprise the following components in parts by weight: 10-25 parts of bifidobacterium longum, 10-15 parts of bifidobacterium breve, 10-35 parts of bifidobacterium bifidum, 10-25 parts of bifidobacterium adolescentis, 10-25 parts of lactobacillus acidophilus, 10-35 parts of lactobacillus fermentum, 10-20 parts of lactobacillus paracasei, 10-30 parts of lactobacillus plantarum, 10-15 parts of lactobacillus rhamnosus and 5-10 parts of streptococcus thermophilus.
Description
Technical Field
The invention relates to the technical field of probiotic preparations, in particular to a probiotic preparation for conditioning intestinal dysbacteriosis of tumor patients after radiotherapy and chemotherapy and application thereof.
Background
The existing probiotic preparation aims at people with high immunity, and the supplemented strains are few in variety and have no pertinence; the components of the probiotic preparations only contain probiotics, and various probiotics have certain mutual competition and mutual inhibition, so that the probiotics for tumor patients with low immunity can become harmful bacteria; the effect of the supplement of probiotics on the imbalance of intestinal flora after the conditioning of radiotherapy and chemotherapy is not great, but the immunity of a tumor patient is not improved; current probiotic embedding techniques are inadequate, resulting in failure of the probiotic to reach the intended site and a low rate of persistent survival.
Disclosure of Invention
The invention provides a probiotic preparation for conditioning intestinal flora imbalance of tumor patients after radiotherapy and chemotherapy, which is used for detecting the intestinal flora in feces of nearly 1500 different tumors of nearly 30 hospitals in 10 different regions across the country, analyzing and summarizing through bioinformatics, formulating different proportions of multiple probiotics, coating the probiotics with naturally extracted oligosaccharides in a vacuum spraying manner according to the characteristics of the different probiotics, and compared with other chemical materials, the naturally extracted oligosaccharides have no toxic or side effect and can provide nutrition for the probiotics, and are simultaneously combined with some components such as proteins, trace elements, vitamins, amino acids and the like which are necessary for organisms in the radiotherapy and chemotherapy process. Aims to adjust the proportion of intestinal flora of a patient, effectively supplement the probiotics and the nutrition required by the organism, start the immunity function of the organism and comprehensively condition the intestinal micro-ecological environment.
A probiotic preparation for conditioning intestinal dysbacteriosis of tumor patients after radiotherapy and chemotherapy is characterized in that: the probiotic preparation comprises probiotics, vitamins, trace elements, proteins, traditional Chinese medicine extracts, sugar and auxiliary components;
the probiotics comprise the following components in parts by weight: 10-25 parts of bifidobacterium longum, 10-15 parts of bifidobacterium breve, 10-35 parts of bifidobacterium bifidum, 10-25 parts of bifidobacterium adolescentis, 10-25 parts of lactobacillus acidophilus, 10-35 parts of lactobacillus fermentum, 10-20 parts of lactobacillus paracasei, 10-30 parts of lactobacillus plantarum, 10-15 parts of lactobacillus rhamnosus and 5-10 parts of streptococcus thermophilus.
The vitamins comprise the following components in percentage by mass: VC is more than 40mg/100g, VE is more than 4mg/100g, VB1 is more than 0.4mg/100g, VB2 is more than 0.5mg/100g, VB6 is more than 0.2mg/100g, VB12 is more than 1 mu g/100g, Vk is more than 25 mu g/100g, and folic acid is more than 30 mu g/100 g.
The trace elements comprise the following components in percentage by mass: fe5-10mg/100g, Mo0.1-0.3mg/100g, Zn2.5-7.5mg/100g, Se2.1-4.2mg/100 g.
The protein comprises the following components in percentage by mass: 5-10g/100g of whey protein.
The traditional Chinese medicine extract comprises the following components in parts by mass: 3-6g/100g of lucid ganoderma extract and 5-15g/100g of astragalus extract.
The sugar comprises the following components in percentage by mass: 2-5g/100g of isomaltooligosaccharide, 5-10g/100g of galacto-oligosaccharide, 5-10g/100g of stachyose and 10-15g/100g of fructo-oligosaccharide.
The auxiliary components comprise the following components in percentage by mass: 1.5-2g/100g of L-glutamine, 1.5-2g/100g of arginine, 2.5-4.5g/100g of mannose and omega-31-2 mg/100 g.
Another object of the invention is to protect the use of said probiotic preparation as a food product for the conditioning of intestinal dysbacteriosis.
The invention has the beneficial effects that: the probiotic preparation provided by the invention comprises 10 types of probiotics which are obviously reduced in intestinal tracts of tumor patients during chemoradiotherapy, and the probiotics is coated by oligosaccharide, so that the damage of digestive juice to the probiotics can be effectively resisted, the activity of probiotic strains is improved, the oligosaccharide coated on the outer layer after reaching a planting position provides nutrition for the probiotics, the planting, survival and amplification of the probiotics are facilitated, and a brain-intestine axis system is activated; in the invention, auxiliary substances such as protein, trace elements, vitamins, amino acid and the like are added, so that the nutritional ingredients necessary for patients in radiotherapy and chemotherapy are accurately supplemented, and the energy is effectively supplemented and the immunity is activated, thereby improving the side effect of the tumor patients in the radiotherapy and chemotherapy and improving the active anti-tumor effect of the organism; the probiotic preparation provided by the invention has no side effect after being taken, and the average effective rate is 95.22%.
Detailed Description
Hereinafter, embodiments of the present invention will be described in detail. The following examples are only for illustrating the technical solutions of the present invention more clearly, and therefore are only examples, and the protection scope of the present invention is not limited thereby.
It is to be noted that, unless otherwise specified, technical or scientific terms used herein shall have the ordinary meaning as understood by those skilled in the art to which the invention pertains.
Example 1
A probiotic preparation for conditioning intestinal dysbacteriosis of tumor patients after radiotherapy and chemotherapy is characterized in that: the probiotic preparation comprises probiotics, vitamins, trace elements, proteins, traditional Chinese medicine extracts, sugar and auxiliary components;
the probiotics comprise the following components in parts by weight: 10 parts of bifidobacterium longum, 10 parts of bifidobacterium breve, 10 parts of bifidobacterium bifidum, 10 parts of bifidobacterium adolescentis, 10 parts of lactobacillus acidophilus, 10 parts of lactobacillus fermentum, 10 parts of lactobacillus paracasei, 10 parts of lactobacillus plantarum, 10 parts of lactobacillus rhamnosus and 5 parts of streptococcus thermophilus.
The vitamins comprise the following components in percentage by mass: VC 45mg/100g, VE 5mg/100g, VB10.5mg/100g, VB20.6mg/100 g, VB60.3mg/100 g, VB 122 mug/100 g, Vk 30 mug/100 g and folic acid 35 mug/100 g.
The trace elements comprise the following components in percentage by mass: fe8mg/100g, Mo0.2mg/100g, Zn5mg/100g and Se3.1mg/100 g.
The protein comprises the following components in percentage by mass: 8g/100g of whey protein.
The traditional Chinese medicine extract comprises the following components in parts by mass: 5g/100g of lucid ganoderma extract and 10g/100g of astragalus extract.
The sugar comprises the following components in percentage by mass: 3g/100g of isomaltooligosaccharide, 8g/100g of galacto-oligosaccharide, 8g/100g of stachyose and 13g/100g of fructo-oligosaccharide.
The auxiliary components comprise the following components in percentage by mass: 1.8g/100g of L-glutamine, 1.8g/100g of arginine, 3.5g/100g of mannose and omega-31.5 mg/100 g.
Example 2
A probiotic preparation for conditioning intestinal dysbacteriosis of tumor patients after radiotherapy and chemotherapy is characterized in that: the probiotic preparation comprises probiotics, vitamins, trace elements, proteins, traditional Chinese medicine extracts, sugar and auxiliary components;
the probiotics comprise the following components in parts by weight: 18 parts of bifidobacterium longum, 13 parts of bifidobacterium breve, 23 parts of bifidobacterium bifidum, 18 parts of bifidobacterium adolescentis, 18 parts of lactobacillus acidophilus, 23 parts of lactobacillus fermentum, 15 parts of lactobacillus paracasei, 20 parts of lactobacillus plantarum, 13 parts of lactobacillus rhamnosus and 8 parts of streptococcus thermophilus.
The vitamins comprise the following components in percentage by mass: VC 45mg/100g, VE 5mg/100g, VB10.5mg/100g, VB20.6mg/100 g, VB60.3mg/100 g, VB 122 mug/100 g, Vk 30 mug/100 g and folic acid 35 mug/100 g.
The trace elements comprise the following components in percentage by mass: fe8mg/100g, Mo0.2mg/100g, Zn5mg/100g and Se3.1mg/100 g.
The protein comprises the following components in percentage by mass: 8g/100g of whey protein.
The traditional Chinese medicine extract comprises the following components in parts by mass: 5g/100g of lucid ganoderma extract and 10g/100g of astragalus extract.
The sugar comprises the following components in percentage by mass: 3g/100g of isomaltooligosaccharide, 8g/100g of galacto-oligosaccharide, 8g/100g of stachyose and 13g/100g of fructo-oligosaccharide.
The auxiliary components comprise the following components in percentage by mass: 1.8g/100g of L-glutamine, 1.8g/100g of arginine, 3.5g/100g of mannose and omega-31.5 mg/100 g.
Example 3
A probiotic preparation for conditioning intestinal dysbacteriosis of tumor patients after radiotherapy and chemotherapy is characterized in that: the probiotic preparation comprises probiotics, vitamins, trace elements, proteins, traditional Chinese medicine extracts, sugar and auxiliary components;
the probiotics comprise the following components in parts by weight: 25 parts of bifidobacterium longum, 15 parts of bifidobacterium breve, 35 parts of bifidobacterium bifidum, 25 parts of bifidobacterium adolescentis, 25 parts of lactobacillus acidophilus, 35 parts of lactobacillus fermentum, 20 parts of lactobacillus paracasei, 30 parts of lactobacillus plantarum, 15 parts of lactobacillus rhamnosus and 10 parts of streptococcus thermophilus.
The vitamins comprise the following components in percentage by mass: VC 45mg/100g, VE 5mg/100g, VB10.5mg/100g, VB20.6mg/100 g, VB60.3mg/100 g, VB 122 mug/100 g, Vk 30 mug/100 g and folic acid 35 mug/100 g.
The trace elements comprise the following components in percentage by mass: fe8mg/100g, Mo0.2mg/100g, Zn5mg/100g and Se3.1mg/100 g.
The protein comprises the following components in percentage by mass: 8g/100g of whey protein.
The traditional Chinese medicine extract comprises the following components in parts by mass: 5g/100g of lucid ganoderma extract and 10g/100g of astragalus extract.
The sugar comprises the following components in percentage by mass: 3g/100g of isomaltooligosaccharide, 8g/100g of galacto-oligosaccharide, 8g/100g of stachyose and 13g/100g of fructo-oligosaccharide.
The auxiliary components comprise the following components in percentage by mass: 1.8g/100g of L-glutamine, 1.8g/100g of arginine, 3.5g/100g of mannose and omega-31.5 mg/100 g.
Test example 1
A total of 482 tumor patients during radiotherapy and chemotherapy were selected from 3 experimental bases, including 110 experimental bases 1, 204 experimental bases 2 and 168 experimental bases 3. The tumor patients with the age of 20-55 years are respectively taken by the probiotic preparations of the examples 1, 2 and 3 in 3 experimental bases.
The dose is as follows: it is administered orally with 1g powder for 2 months after 3 times per day.
The effective rate statistics were carried out, and the results are shown in table 1.
Effective rate (%) - (significant number of effective persons + number of effective persons) ÷ (significant number of effective persons + number of ineffective persons + number of side effects) × 100%
TABLE 1 therapeutic effect table of probiotic preparation for regulating intestinal dysbacteriosis of tumor patients after radiotherapy and chemotherapy
As can be seen from the data in table 1, the probiotic preparations of examples 1 to 3 of the present invention have no side effects, with a maximum effective rate of 96.43% and an average effective rate of 95.22%.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; such modifications and substitutions do not depart from the spirit and scope of the present invention, and they should be construed as being included in the following claims and description.
Claims (8)
1. A probiotic preparation for conditioning intestinal dysbacteriosis of tumor patients after radiotherapy and chemotherapy is characterized in that: the probiotic preparation comprises probiotics, vitamins, trace elements, proteins, traditional Chinese medicine extracts, sugar and auxiliary components; the probiotics comprise the following components in parts by weight: 10-25 parts of bifidobacterium longum, 10-15 parts of bifidobacterium breve, 10-35 parts of bifidobacterium bifidum, 10-25 parts of bifidobacterium adolescentis, 10-25 parts of lactobacillus acidophilus, 10-35 parts of lactobacillus fermentum, 10-20 parts of lactobacillus paracasei, 10-30 parts of lactobacillus plantarum, 10-15 parts of lactobacillus rhamnosus and 5-10 parts of streptococcus thermophilus.
2. The probiotic formulation according to claim 1, characterized in that: the vitamins comprise the following components in percentage by mass: VC is more than 40mg/100g, VE is more than 4mg/100g, VB1 is more than 0.4mg/100g, VB2 is more than 0.5mg/100g, VB6 is more than 0.2mg/100g, VB12 is more than 1 mu g/100g, Vk is more than 25 mu g/100g, and folic acid is more than 30 mu g/100 g.
3. The probiotic formulation according to claim 2, characterized in that: the trace elements comprise the following components in percentage by mass: fe5-10mg/100g, Mo0.1-0.3mg/100g, Zn2.5-7.5mg/100g, Se2.1-4.2mg/100 g.
4. The probiotic formulation according to claim 3, characterized in that: the protein comprises the following components in parts by mass: 5-10g/100g of whey protein.
5. The probiotic formulation according to claim 4, characterized in that: the traditional Chinese medicine extract comprises the following components in parts by mass: 3-6g/100g of lucid ganoderma extract and 5-15g/100g of astragalus extract.
6. The probiotic formulation according to claim 5, characterized in that: the sugar comprises the following components in parts by mass: 2-5g/100g of isomaltooligosaccharide, 5-10g/100g of galacto-oligosaccharide, 5-10g/100g of stachyose and 10-15g/100g of fructo-oligosaccharide.
7. The probiotic formulation according to claim 5, characterized in that: the auxiliary components comprise the following components in percentage by mass: 1.5-2g/100g of L-glutamine, 1.5-2g/100g of arginine, 2.5-4.5g/100g of mannose and omega-31-2 mg/100 g.
8. Use of a probiotic formulation according to claims 1-7 as a food product for the conditioning of intestinal dysbacteriosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911283572.4A CN110882282A (en) | 2019-12-13 | 2019-12-13 | Probiotic preparation for conditioning intestinal dysbacteriosis of tumor patients after radiotherapy and chemotherapy and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911283572.4A CN110882282A (en) | 2019-12-13 | 2019-12-13 | Probiotic preparation for conditioning intestinal dysbacteriosis of tumor patients after radiotherapy and chemotherapy and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110882282A true CN110882282A (en) | 2020-03-17 |
Family
ID=69751846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911283572.4A Pending CN110882282A (en) | 2019-12-13 | 2019-12-13 | Probiotic preparation for conditioning intestinal dysbacteriosis of tumor patients after radiotherapy and chemotherapy and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110882282A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111494431A (en) * | 2020-04-28 | 2020-08-07 | 苏州大学 | Application of probiotics in preparation of preparation for treating liver diseases |
| CN113750129A (en) * | 2021-09-17 | 2021-12-07 | 无锡弘焕微生态科技有限公司 | Traditional Chinese medicine probiotic fermentation liquor preparation for relieving side effects of chemotherapy |
| CN115927106A (en) * | 2022-12-16 | 2023-04-07 | 南方医科大学南方医院 | Rhamnose cheese bacillus DY801 and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009157759A1 (en) * | 2008-06-23 | 2009-12-30 | N.V. Nutricia | Nutritional composition for improving the mammalian immune system |
| CN104207139A (en) * | 2014-07-28 | 2014-12-17 | 胡安然 | Total-nutritional formulation food used for tumor |
| MY158393A (en) * | 2009-11-24 | 2016-10-14 | Univ Putra Malaysia | Tumour cytotoxic agent and methods thereof |
-
2019
- 2019-12-13 CN CN201911283572.4A patent/CN110882282A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009157759A1 (en) * | 2008-06-23 | 2009-12-30 | N.V. Nutricia | Nutritional composition for improving the mammalian immune system |
| MY158393A (en) * | 2009-11-24 | 2016-10-14 | Univ Putra Malaysia | Tumour cytotoxic agent and methods thereof |
| CN104207139A (en) * | 2014-07-28 | 2014-12-17 | 胡安然 | Total-nutritional formulation food used for tumor |
Non-Patent Citations (1)
| Title |
|---|
| 陈明岭等: "《皮肤病常用中药药理及临床 第2版》", 31 October 2017, 中国科学技术出版社 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111494431A (en) * | 2020-04-28 | 2020-08-07 | 苏州大学 | Application of probiotics in preparation of preparation for treating liver diseases |
| CN111494431B (en) * | 2020-04-28 | 2021-06-22 | 苏州大学 | Application of probiotics in preparation of preparation for treating liver diseases |
| CN113750129A (en) * | 2021-09-17 | 2021-12-07 | 无锡弘焕微生态科技有限公司 | Traditional Chinese medicine probiotic fermentation liquor preparation for relieving side effects of chemotherapy |
| CN115927106A (en) * | 2022-12-16 | 2023-04-07 | 南方医科大学南方医院 | Rhamnose cheese bacillus DY801 and application thereof |
| CN115927106B (en) * | 2022-12-16 | 2023-09-08 | 南方医科大学南方医院 | Lactobacillus rhamnosus DY801 and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110882282A (en) | Probiotic preparation for conditioning intestinal dysbacteriosis of tumor patients after radiotherapy and chemotherapy and application thereof | |
| EP3412766B1 (en) | Lactobacillus salivarius strain, composition comprising the same, and uses thereof | |
| EP2305838B1 (en) | Bifidobacteria that produces folic acid, food composition and use of said bifidobacteria | |
| KR101228608B1 (en) | Probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of the intestinal functionality | |
| CN113180109B (en) | Application of lactobacillus reuteri in preparation of products for preventing or treating developmental disorder diseases | |
| Kumari et al. | Clinical importance of lactic acid bacteria: a short review | |
| US20150079041A1 (en) | Bacterial composition and its use | |
| CN112805020A (en) | Antitumor effect potentiator | |
| EP3808357A1 (en) | Composition and uses thereof | |
| Kim et al. | The effect of Lactobacillus casei extract on cervical cancer cell lines | |
| EP4081231A1 (en) | Compositions comprising microbes and methods of use and making thereof | |
| CN108697742A (en) | Composition for preventing and/or treating vitamin B12 deficiency disease and method | |
| US20200316023A1 (en) | Method Of Producing Bacterially Derived Indole-3-Propionic Acid And Compositions Comprising Same | |
| TW201623626A (en) | Lactic acid bacterium having purine body uptake ability, and use thereof | |
| Salminen et al. | Safety assessment of Lactobacillus strain GG (ATCC 53103) | |
| EP2032148A2 (en) | Composition containing lactobacillus sp. and a cannabinoid receptor and/or a opioid receptor agonist | |
| WO2019227414A1 (en) | Composition and uses thereof | |
| TW202322831A (en) | Anti-aging composition and use thereof for preventing aging | |
| Duffy et al. | Perspectives on bifidobacteria as biotherapeutic agents in gastrointestinal health | |
| Tochilina et al. | Genome Features of Probiotic Bifidobacteria Determining Their Strain-Specific Properties | |
| TWI764356B (en) | Anti-aging composition including strains of lactic acid bacteria or a ferment thereof and use of the composition | |
| CN110090230B (en) | Application of bacillus coagulans in preparation of preparation for preventing or treating cholangiocarcinoma | |
| Zawistowska-Rojek et al. | How to Improve Health with Biological Agents—Narrative Review. Nutrients 2022, 14, 1700 | |
| Patil et al. | Improving the Gut Microbiota with Probiotics and Faecal Microbiota Transplantation. | |
| Devika Das et al. | Modern Perspectives in Controlling Human Diseases through Probiotic Intervention |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200317 |
|
| RJ01 | Rejection of invention patent application after publication |